drugset
drugset / Trial / NCT04528836

First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors

NCT04528836 ↗

Phase 1 Terminated 72 enrolled Navire Pharma Inc., a BridgeBio company
Non-randomizedSequentialOpen-labelTreatment

Summary

A first-in-human study to evaluate the safety, tolerability and maximum tolerated dose (MTD) and establish the recommended phase 2 dose (RP2D) of BBP-398, a SHP2 inhibitor, in patients with advanced solid tumors.

Timeline

Start
2020-11-12
Primary completion
2024-03-22
Completion
2024-07-30

Drugs

EvaluationDrugModalityDoseRoute
Subject BBP-398 Small molecule — Oral

Indications

No indication recorded.